Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dendritic cell subsets and type I diabetes: focus upon DC-based therapy.

Jeannette Lo1, Michael J Clare-Salzler

  • 1Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, P.O.Box 100275, 1600 SW Archer Road, Gainesville, FL 32610, Gainesville, USA.

Autoimmunity Reviews
|August 8, 2006
PubMed
Summary

Dendritic cell (DC) therapy shows promise for treating Type I diabetes (TID) by modulating immune responses. Engineering specific DC subsets and using T1D antigens may enhance regulatory T-cell activity for autoimmune disease treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zigakibart Potently Inhibits A Proliferation-Inducing Ligand-Mediated IgA Production, Addressing IgAN Pathogenesis Root Causes.

Kidney international reports·2026
Same author

Optimizing COVID-19 testing capabilities and clinical management using pathology informatics.

JAMIA open·2021
Same author

Influence of Vitamin D on Islet Autoimmunity and Beta-Cell Function in Type 1 Diabetes.

Nutrients·2019
Same author

Dual-Sized Microparticle System for Generating Suppressive Dendritic Cells Prevents and Reverses Type 1 Diabetes in the Nonobese Diabetic Mouse Model.

ACS biomaterials science & engineering·2019
Same author

Evaluation of <i>in vitro</i> Assays to Assess the Modulation of Dendritic Cells Functions by Therapeutic Antibodies and Aggregates.

Frontiers in immunology·2019
Same author

CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial.

Genetics in medicine : official journal of the American College of Medical Genetics·2019

Area of Science:

  • Immunology
  • Endocrinology
  • Cell Biology

Background:

  • Type I diabetes (TID) involves autoimmune destruction of insulin-producing beta cells, driven by T cells.
  • A Th1-dominant immune response against autoantigens like GAD and insulin, coupled with weak regulation, underlies TID pathogenesis.
  • Dendritic cells (DCs), as professional antigen-presenting cells (APCs), play a crucial role in directing T cell immunity versus regulation.

Purpose of the Study:

  • To review advances in dendritic cell (DC) therapy for Type I diabetes (TID) treatment.
  • To explore strategies for engineering DCs to augment regulatory immune responses for autoimmune disease management.
  • To discuss the selection of DC subsets, antigens, and administration routes for optimizing DC-based immunotherapy in TID.

Main Methods:

Related Experiment Videos

  • Review of current research on dendritic cell (DC) subsets and their function in T cell priming and regulation.
  • Analysis of strategies for engineering DCs for therapeutic purposes in autoimmune diseases.
  • Examination of antigen-specific DC-based therapy approaches for Type I diabetes (TID).

Main Results:

  • Dendritic cells (DCs) can be manipulated to either promote effector T cells or induce regulatory T cells.
  • Engineering specific DC subsets and utilizing T1D-associated antigens are key to developing effective DC-based therapies.
  • The choice of DC subset, antigen, and administration route significantly impacts immunotherapy outcomes.

Conclusions:

  • Dendritic cell (DC) therapy holds significant potential for preventing and treating Type I diabetes (TID) by enhancing regulatory immune responses.
  • Tailoring DC subsets and antigen presentation is critical for successful immunotherapy in autoimmune diseases.
  • Further research into optimizing DC-based strategies is essential for advancing TID treatment.